Wall Street Zen upgraded shares of Iambic Therapeutics (NASDAQ:IAM – Free Report) to a hold rating in a research report report published on Saturday,Wall Street Zen reports.
Iambic Therapeutics Trading Up 31.6%
NASDAQ:IAM opened at $13.38 on Friday. Iambic Therapeutics has a 12-month low of $9.60 and a 12-month high of $25.00.
Insider Buying and Selling at Iambic Therapeutics
In related news, Director Evan Lockwood Rachlin acquired 718,750 shares of the stock in a transaction dated Friday, October 16th. The shares were bought at an average cost of $16.00 per share, for a total transaction of $11,500,000.00. Following the purchase, the director owned 2,588,248 shares in the company, valued at approximately $41,411,968. This trade represents a 38.45% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 22.90% of the company’s stock.
Iambic Therapeutics Company Profile
Further Reading
- Five stocks we like better than Iambic Therapeutics
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for Iambic Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iambic Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
